Cargando…

Targeting undruggable carbohydrate recognition sites through focused fragment library design

Carbohydrate-protein interactions are key for cell-cell and host-pathogen recognition and thus, emerged as viable therapeutic targets. However, their hydrophilic nature poses major limitations to the conventional development of drug-like inhibitors. To address this shortcoming, four fragment librari...

Descripción completa

Detalles Bibliográficos
Autores principales: Shanina, Elena, Kuhaudomlarp, Sakonwan, Siebs, Eike, Fuchsberger, Felix F., Denis, Maxime, da Silva Figueiredo Celestino Gomes, Priscila, Clausen, Mads H., Seeberger, Peter H., Rognan, Didier, Titz, Alexander, Imberty, Anne, Rademacher, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814205/
https://www.ncbi.nlm.nih.gov/pubmed/36697615
http://dx.doi.org/10.1038/s42004-022-00679-3
Descripción
Sumario:Carbohydrate-protein interactions are key for cell-cell and host-pathogen recognition and thus, emerged as viable therapeutic targets. However, their hydrophilic nature poses major limitations to the conventional development of drug-like inhibitors. To address this shortcoming, four fragment libraries were screened to identify metal-binding pharmacophores (MBPs) as novel scaffolds for inhibition of Ca(2+)-dependent carbohydrate-protein interactions. Here, we show the effect of MBPs on the clinically relevant lectins DC-SIGN, Langerin, LecA and LecB. Detailed structural and biochemical investigations revealed the specificity of MBPs for different Ca(2+)-dependent lectins. Exploring the structure-activity relationships of several fragments uncovered the functional groups in the MBPs suitable for modification to further improve lectin binding and selectivity. Selected inhibitors bound efficiently to DC-SIGN-expressing cells. Altogether, the discovery of MBPs as a promising class of Ca(2+)-dependent lectin inhibitors creates a foundation for fragment-based ligand design for future drug discovery campaigns.